These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 34671446)

  • 1. 2-Imidazole as a Substitute for the Electrophilic Group Gives Highly Potent Prolyl Oligopeptidase Inhibitors.
    Pätsi HT; Kilpeläinen TP; Auno S; Dillemuth PMJ; Arja K; Lahtela-Kakkonen MK; Myöhänen TT; Wallén EAA
    ACS Med Chem Lett; 2021 Oct; 12(10):1578-1584. PubMed ID: 34671446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tetrazole as a Replacement of the Electrophilic Group in Characteristic Prolyl Oligopeptidase Inhibitors.
    Kilpeläinen TP; Tyni JK; Lahtela-Kakkonen MK; Eteläinen TS; Myöhänen TT; Wallén EAA
    ACS Med Chem Lett; 2019 Dec; 10(12):1635-1640. PubMed ID: 31857839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of prolyl oligopeptidase inhibitors on alpha-synuclein aggregation and autophagy cannot be predicted by their inhibitory efficacy.
    Kilpeläinen TP; Hellinen L; Vrijdag J; Yan X; Svarcbahs R; Vellonen KS; Lambeir AM; Huttunen H; Urtti A; Wallen EAA; Myöhänen TT
    Biomed Pharmacother; 2020 Aug; 128():110253. PubMed ID: 32447211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-Aminothiazoles Reveal a New Ligand-Binding Site on Prolyl Oligopeptidase Which is Important for Modulation of Its Protein-Protein Interaction-Derived Functions.
    Pätsi HT; Kilpeläinen TP; Jumppanen M; Uhari-Väänänen J; Wielendaele PV; De Lorenzo F; Cui H; Auno S; Saharinen J; Seppälä E; Sipari N; Savinainen J; De Meester I; Lambeir AM; Lahtela-Kakkonen M; Myöhänen TT; Wallén EAA
    J Med Chem; 2024 Apr; 67(7):5421-5436. PubMed ID: 38546708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolyl oligopeptidase enhances α-synuclein dimerization via direct protein-protein interaction.
    Savolainen MH; Yan X; Myöhänen TT; Huttunen HJ
    J Biol Chem; 2015 Feb; 290(8):5117-5126. PubMed ID: 25555914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New tricks of prolyl oligopeptidase inhibitors - A common drug therapy for several neurodegenerative diseases.
    Svarcbahs R; Julku U; Kilpeläinen T; Kyyrö M; Jäntti M; Myöhänen TT
    Biochem Pharmacol; 2019 Mar; 161():113-120. PubMed ID: 30660495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The beneficial effect of a prolyl oligopeptidase inhibitor, KYP-2047, on alpha-synuclein clearance and autophagy in A30P transgenic mouse.
    Savolainen MH; Richie CT; Harvey BK; Männistö PT; Maguire-Zeiss KA; Myöhänen TT
    Neurobiol Dis; 2014 Aug; 68():1-15. PubMed ID: 24746855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition-mediated changes in prolyl oligopeptidase dynamics possibly related to α-synuclein aggregation.
    Walczewska-Szewc K; Rydzewski J; Lewkowicz A
    Phys Chem Chem Phys; 2022 Feb; 24(7):4366-4373. PubMed ID: 35112120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolyl oligopeptidase inhibition by KYP-2407 increases alpha-synuclein fibril degradation in neuron-like cells.
    Rostami J; Jäntti M; Cui H; Rinne MK; Kukkonen JP; Falk A; Erlandsson A; Myöhänen T
    Biomed Pharmacother; 2020 Nov; 131():110788. PubMed ID: 33152946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P2-substituted N-acylprolylpyrrolidine inhibitors of prolyl oligopeptidase: biochemical evaluation, binding mode determination, and assessment in a cellular model of synucleinopathy.
    Van der Veken P; Fülöp V; Rea D; Gerard M; Van Elzen R; Joossens J; Cheng JD; Baekelandt V; De Meester I; Lambeir AM; Augustyns K
    J Med Chem; 2012 Nov; 55(22):9856-67. PubMed ID: 23121075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolyl oligopeptidase and dipeptidyl peptidase II/dipeptidyl peptidase IV ratio in the cerebrospinal fluid in Parkinson's disease: historical overview and future prospects.
    Nagatsu T
    J Neural Transm (Vienna); 2017 Jun; 124(6):739-744. PubMed ID: 27503084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolyl oligopeptidase inhibition reduces oxidative stress via reducing NADPH oxidase activity by activating protein phosphatase 2A.
    Eteläinen T; Kulmala V; Svarcbahs R; Jäntti M; Myöhänen TT
    Free Radic Biol Med; 2021 Jun; 169():14-23. PubMed ID: 33838285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prolyl oligopeptidase inhibitor, KYP-2047, reduces α-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease.
    Myöhänen TT; Hannula MJ; Van Elzen R; Gerard M; Van Der Veken P; García-Horsman JA; Baekelandt V; Männistö PT; Lambeir AM
    Br J Pharmacol; 2012 Jun; 166(3):1097-113. PubMed ID: 22233220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolyl oligopeptidase inhibition attenuates the toxicity of a proteasomal inhibitor, lactacystin, in the alpha-synuclein overexpressing cell culture.
    Myöhänen TT; Norrbacka S; Savolainen MH
    Neurosci Lett; 2017 Jan; 636():83-89. PubMed ID: 27818354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolyl oligopeptidase colocalizes with α-synuclein, β-amyloid, tau protein and astroglia in the post-mortem brain samples with Parkinson's and Alzheimer's diseases.
    Hannula MJ; Myöhänen TT; Tenorio-Laranga J; Männistö PT; Garcia-Horsman JA
    Neuroscience; 2013 Jul; 242():140-50. PubMed ID: 23562579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolyl oligopeptidase inhibition activates autophagy via protein phosphatase 2A.
    Svarcbahs R; Jäntti M; Kilpeläinen T; Julku UH; Urvas L; Kivioja S; Norrbacka S; Myöhänen TT
    Pharmacol Res; 2020 Jan; 151():104558. PubMed ID: 31759088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of Action of Prolyl Oligopeptidase (PREP) in Degenerative Brain Diseases: Has Peptidase Activity Only a Modulatory Role on the Interactions of PREP with Proteins?
    Männistö PT; García-Horsman JA
    Front Aging Neurosci; 2017; 9():27. PubMed ID: 28261087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolyl Oligopeptidase Regulates Dopamine Transporter Phosphorylation in the Nigrostriatal Pathway of Mouse.
    Julku UH; Panhelainen AE; Tiilikainen SE; Svarcbahs R; Tammimäki AE; Piepponen TP; Savolainen MH; Myöhänen TT
    Mol Neurobiol; 2018 Jan; 55(1):470-482. PubMed ID: 27966077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of prolyl oligopeptidase increases the survival of alpha-synuclein overexpressing cells after rotenone exposure by reducing alpha-synuclein oligomers.
    Dokleja L; Hannula MJ; Myöhänen TT
    Neurosci Lett; 2014 Nov; 583():37-42. PubMed ID: 25240592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolyl oligopeptidase acts as a link between chaperone-mediated autophagy and macroautophagy.
    Cui H; Norrbacka S; Myöhänen TT
    Biochem Pharmacol; 2022 Mar; 197():114899. PubMed ID: 34968496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.